Last reviewed · How we verify

ITB-Med LLC — Portfolio Competitive Intelligence Brief

ITB-Med LLC pipeline: 3 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Mycophenolate Mofetil (MMF) Mycophenolate Mofetil (MMF) marketed Inosine monophosphate dehydrogenase (IMPDH) inhibitor IMPDH type II Immunology
Tacrolimus (TAC) Tacrolimus (TAC) marketed Calcineurin inhibitor Calcineurin (protein phosphatase 2B) Immunology
ATG ATG marketed Polyclonal antithymocyte antibody T-cell surface antigens (CD2, CD3, CD4, CD8, and other T-cell markers) Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. East Carolina University · 2 shared drug classes
  2. University Hospital, Limoges · 2 shared drug classes
  3. Hoffmann-La Roche · 2 shared drug classes
  4. Allergan · 1 shared drug class
  5. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  6. Astellas Pharma China, Inc. · 1 shared drug class
  7. Armando Torres Ramírez · 1 shared drug class
  8. Astellas Pharma Europe Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for ITB-Med LLC:

Cite this brief

Drug Landscape (2026). ITB-Med LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/itb-med-llc. Accessed 2026-05-15.

Related